Table 1: Bristol-Myers Squibb – PharmaVitae forecasts at a glance 5
Table 2: Plavix demise set to override 2007–13 growth prospects 5
Table 3: BMS’s therapeutic transformation ($m), 2007–13 5
Table 4: Bristol-Myers Squibb key product developments, Q1-Q2 2008 5
Table 5: Bristol-Myers Squibb product deals and alliances, Q1-Q2 2008 5
Table 6: Bristol-Myers Squibb technology deals and alliances, Q1-Q2 2008 5
Table 7: Bristol-Myers Squibb M&A activity, Q1-Q2 2008 5
Table 8: Bristol-Myers Squibb company announcements, Q1-Q2 2008 5
Table 9: Bristol-Myers Squibb future product milestones, 2008–10 5
Table 10: Bristol-Myers Squibb product portfolio overview ($m), 2001–07 5
Table 11: Bristol-Myers Squibb product portfolio overview ($m), 2007–13 5
Table 12: Bristol-Myers Squibb therapy portfolio overview ($m), 2001–07 5
Table 13: Bristol-Myers Squibb therapy portfolio overview ($m), 2007–13 5
Table 14: Bristol-Myers Squibb portfolio overview by geographic region ($m), 2001–07 5
Table 15: Bristol-Myers Squibb portfolio overview by geographic region ($m), 2007–13 5
Table 16: Bristol-Myers Squibb launch portfolio overview ($m), 2007–13 5
Table 17: Bristol-Myers Squibb core portfolio overview ($m), 2007–13 5
Table 18: Bristol-Myers Squibb expiry portfolio overview ($m), 2007–13 5
Table 19: Bristol-Myers Squibb portfolio overview by molecule type ($m), 2001–07 5
Table 20: Bristol-Myers Squibb product portfolio overview by molecule type ($m), 2007–13 5
Table 21: Bristol-Myers Squibb product portfolio overview by source ($m), 2001–07 5
Table 22: Bristol-Myers Squibb product portfolio overview by source ($m), 2007–13 5
Table 23: Total Bristol-Myers Squibb sales by business unit ($m), 2001–07 5
Table 24: Bristol-Myers Squibb profit and loss account ($m), 2001–07 5
Table 25: Bristol-Myers Squibb balance sheet ($m), 2001–07 5
Table 26: Bristol-Myers Squibb operating revenue/cost analysis ($m), 2001–07 5
Table 27: Bristol-Myers Squibb operating cost ratio analysis (% of total revenues), 2001–07 5
Table 28: Bristol-Myers Squibb operating cost ratio analysis (% of total revenues), 2007–13 5
Table 29: Bristol-Myers Squibb operating revenue/cost analysis ($m), 2007–13 5
Table 30: Bristol-Myers Squibb capital employed ($m), 2001–07 5
Table 31: Bristol-Myers Squibb EBIT return on capital employed ($m), 2001–07 5
Table 32: Bristol-Myers Squibb EBIT pre-tax return/Capital employed driver analysis (%), 2001–07 5
Table 33: Bristol-Myers Squibb market capitalization ($ billion), 2001–07 5
Table 34: Bristol-Myers Squibb total shareholder returns (annual %), 2001–07 5
Table 35: Key products overview 5
Table 36: Erbitux: overview 5
Table 37: Erbitux: sales forecast ($m), 2007–13 5
Table 38: Sprycel: overview 5
Table 39: Sprycel: sales forecast ($m), 2007–13 5
Table 40: Ixempra: overview 5
Table 41: Ixempra: sales forecast ($m), 2007–13 5
Table 42: Sustiva franchise: overview 5
Table 43: Sustiva franchise: sales forecast ($m), 2007–13 5
Table 44: Reyataz: overview 5
Table 45: Reyataz: sales forecast ($m), 2007–13 5
Table 46: Orencia: overview 5
Table 47: Orencia: sales forecast ($m), 2007–13 5
Table 48: Plavix: overview 5
Table 49: Plavix: sales forecast ($m), 2007–13 5
Table 50: Abilify: overview 5
Table 51: Abilify: sales forecast ($m), 2007–13 5
Table 52: Onglyza: overview 5
Table 53: Onglyza: sales forecast ($m), 2007–13 5
Table 54: Bristol-Myers Squibb’s R&D pipeline (Phase I–registration) 5
Table 55: Exchange rates, 2007 5
Figure 1: Bristol-Myers Squibb prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001–13 5
Figure 2: Bristol-Myers Squibb’s financial performance ($m), 2001–13 5
Figure 3: Plavix sales dependency (% of total), 2001–13 5
Figure 4: Bristol-Myers Squibb prescription pharma sales by therapy area (% of total), 2001–13 5
Figure 5: Bristol-Myers Squibb SWOT analysis 5
Figure 6: Current corporate structure 5
Figure 7: Bristol-Myers Squibb prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001–13 5
Figure 8: Bristol-Myers Squibb key sales growth driver & resistors ($m), 2001–07 5
Figure 9: Bristol-Myers Squibb key sales growth drivers & resistors ($m), 2007–13 5
Figure 10: Bristol-Myers Squibb prescription pharmaceutical sales by therapy area ($m), 2001–13 5
Figure 11: Bristol-Myers Squibb prescription pharma sales by therapy area (% of total), 2001–13 5
Figure 12: Bristol-Myers Squibb prescription pharmaceutical sales by geographic region ($m), 2001–13 5
Figure 13: Bristol-Myers Squibb drivers and resistors by geographic region ($m), 2001–07 5
Figure 14: Bristol-Myers Squibb drivers and resistors by geographic region ($m), 2007–13 5
Figure 15: Bristol-Myers Squibb prescription pharmaceutical sales by geographic region (% of total), 2001–13 5
Figure 16: Bristol-Myers Squibb launch/core/expiry configuration ($m), 2007–13 5
Figure 17: Bristol-Myers Squibb prescription pharmaceutical sales by molecule type ($m), 2001–13 5
Figure 18: Bristol-Myers Squibb growth drivers & resistors by molecule type ($m), 2007–13 5
Figure 19: Bristol-Myers Squibb prescription pharmaceutical sales by source ($m), 2001–13 5
Figure 20: Bristol-Myers Squibb growth drivers & resistors by source ($m), 2001–07 5
Figure 21: Bristol-Myers Squibb growth drivers & resistors by source ($m), 2007–13 5
Figure 22: Bristol-Myers Squibb operating revenue/cost analysis ($m), 2001–13 5
Figure 23: Bristol-Myers Squibb operating cost ratio analysis (% of total revenues), 2001–13 5
Figure 24: Bristol-Myers Squibb return on capital employed, EBIT margin and capital turnover, 2001–07 5
Figure 25: Return on capital employed formula 5
Figure 26: Bristol-Myers Squibb market capitalization ($ billion), 2001–07 5
Figure 27: Bristol-Myers Squibb total shareholder returns vs. S&P 500 ($m), 2001–07 5
[Tabellenverzeichnis ausblenden]
